Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

Pharmacogenetics and Genomics

Volumn 22, Issue 1, 2012, Pages 10-19

  Liptrott, Neill J ^a,b   Pushpakom, Sudeep ^a,b   Wyen, Christoph ^c   Fätkenheuer, Gerd ^c   Hoffmann, Christian ^d   Mauss, Stefan ^e   Knechten, Heribert ^f   Brockmeyer, Norbert H ^g   Hopper Borge, Elizabeth ^h   Siccardi, Marco ^a   Back, David J ^a   Khoo, Saye H ^a   Pirmohamed, Munir ^a,b   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e Center for HIV and Hepatogastroenterology   (Germany)

^f Praxen Zentrum Blondelstrasse   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h FOX CHASE CANCER CENTER   (United States)

Author keywords

ABCC10; drug efflux transporter; HIV; monocyte derived macrophage; nevirapine; single nucleotide polymorphism

Indexed keywords

ADEFOVIR DIPIVOXIL; ATAZANAVIR; CEPHARANTHINE; DARUNAVIR; DNA; EFAVIRENZ; LOPINAVIR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 7; NEVIRAPINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CAUCASIAN; CD4+ T LYMPHOCYTE; CELL STRAIN HEK293; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG METABOLISM; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; GERMANY; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MACROPHAGE; MAJOR CLINICAL STUDY; NEGRO; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 83655201204     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834dd82e     Document Type: Article

References (33)

1. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000; 44:2475-2484. (Pubitemid 30650898)
2. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21:2191-2199. (Pubitemid 350287217)
3. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, et al. Impact of CYP2B6 983T
4. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8:86-91. (Pubitemid 46390844)
5. Janneh O, Chandler B, Hartkoorn R, Kwan WS, Jenkinson C, Evans S, et al. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2009; 64:1002-1007.
6. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch 2007; 453:675-684. (Pubitemid 46192538)
7. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, et al. Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2009; 77:993-1001.
8. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006; 36:963-988. (Pubitemid 44844110)
9. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 2009; 69:178-184.
10. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, Labarga P, Soriano V, Albalater M, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011; 204: 145-153.
11. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 2004; 64:4927-4930. (Pubitemid 38924539)
12. Liptrott NJ, Khoo SH, Back DJ, Owen A. Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. J Immunol Methods 2008; 339:270-274.
13. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33:1595-1597. (Pubitemid 34246157)
14. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat Genet 2001; 29:229-232. (Pubitemid 32952664)
15. Pushpakom SP, Liptrott NJ, Rodríguez-Nó voa S, Labarga P, Soriano V, Albalater M, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011; 204: 145-153.
16. Molto J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, et al. Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol 2007; 63:715-721. (Pubitemid 46753571)
17. Kappelhoff BS, Van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10:489-498. (Pubitemid 41059195)
18. De Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42:599-605. (Pubitemid 36805618)
19. Duong M, Buisson M, Peytavin G, Kohli E, Piroth L, Martha B, et al. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother 2005; 39:603-609. (Pubitemid 40396611)
20. Gonzalez de Requena D, Bonora S, Garazzino S, Sciandra M, D'Avolio A, Raiteri R, et al. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 2005; 49:3966-3969. (Pubitemid 41233062)
21. De Maat MM, Huitema AD, Mulder JW, Meenhorst PL, Van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54:378-385. (Pubitemid 35334950)
22. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003; 47:130-137. (Pubitemid 36070353)
23. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther 2005; 10:937-943. (Pubitemid 43076345)
24. Mahungu T, Smith C, Turner F, Egan D, Youle M, Johnson M, et al. Cytochrome P450 2B6 516G-
25. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35:340-344. (Pubitemid 46333919)
26. De Maat MM, ter Heine R, Mulder JW, Meenhorst PL, Mairuhu AT, Van Gorp EC, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59:457-462. (Pubitemid 37214954)
27. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15: 1089-1095. (Pubitemid 32549859)
28. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 2003; 63: 351-358. (Pubitemid 36158370)
29. Liptrott NJ, Penny M, Bray PG, Sathish J, Khoo SH, Back DJ, et al. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol 2009; 156:497-508.
30. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 (Suppl 1):S5-S37.
31. ElSharawy A, Hundrieser B, Brosch M, Wittig M, Huse K, Platzer M, et al. Systematic evaluation of the effect of common SNPs on pre-mRNA splicing. Hum Mutat 2009; 30:625-632.
32. Uttayamakul S, Likanonsakul S, Manosuthi W,Wichukchinda N, Kalambaheti T, Nakayama EE, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010; 7:8.
33. Zahedi P, De Souza R, Huynh L, Piquette-Miller M, Allen C. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. Mol Pharm 2011; 8:260-269.